North America Non-Alcoholic Steatohepatitis Market Forecast to 2028

Report Code : BMIRE00025407 | Region : North America | Industry : Pharmaceuticals | Published Date : 18/Jul/2022
North America Non-Alcoholic Steatohepatitis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)

The North America non-alcoholic steatohepatitis market is expected to reach US$ 12,963.42 million by 2028 from US$ 838.07 million in 2021. The market is estimated to grow at a CAGR of 47.9% from 2021 to 2028.

Non-alcoholic steatohepatitis (NASH) is a potentially fatal illness that causes extensive scarring and cirrhosis in the liver. Non-alcoholic fatty liver disease (NAFLD) is North America's most common chronic liver disease. NASH is a progressive form of NAFLD, which is gradually becoming the major cause of end-stage liver diseases and liver transplantation. According to the data published by the Global Liver Institute on June 12, 2019, non-alcoholic steatohepatitis (NASH) has been called an epidemic. Furthermore, it is a progressive type of non-alcoholic fatty liver disease (NAFLD) that affects over ~115 million people and by 2030, 357 million people are expected to be affected. Obesity, type 2 diabetes, and hyperlipidemia are substantial risk factors for NAFLD and NASH: more than ~70% of people are obese, ~75% have type 2 diabetes, and 20-80% have hyperlipidemia. NASH, if left untreated, can progress to cirrhosis, liver cancer, and the need for a liver transplant. As per the data published by the American Liver Foundation, NAFLD is the most common chronic liver disease in the US. It is projected that ~25% of adults in the US have NAFLD, out of which ~20% have NASH, which is 5% of adults in the US. According to the NASH Education Program, NASH prevalence is expected to increase by 63% between 2015 and 2030. Between 2020 and 2025, NASH is predicted to become the major cause of liver transplantation in the US. The American Association for the Study of Liver Diseases published a report in 2018 using Markov modeling to forecast NAFLD disease by 2030 and observed that the prevalence of NAFLD and NASH cases are forecasted to increase by 21% and 63%, respectively, providing 33.5% and 27% prevalence rate of NAFLD and NASH in adults, respectively. Despite its increasing prevalence, NAFLD/NASH remains an under-recognized condition, and early detection is critical to reducing the risk of progression and its associated consequences. Thus, the growing prevalence of NASH is expected to drive the non-alcoholic steatohepatitis (NASH) market. The North America Non-Alcoholic Steatohepatitis market is expected to grow at a good CAGR during the forecast period.

North America Non-Alcoholic Steatohepatitis Revenue and Forecast to 2028 (US$ Million)

North America Non-Alcoholic Steatohepatitis Market Segmentation

The North America Non-Alcoholic Steatohepatitis market segmented into product, application, sales channel and country. Based on product type the North America Non-Alcoholic Steatohepatitis market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib,cenicriviroc and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period .Based on application the North America Non-Alcoholic Steatohepatitis market segmented into treatment and diagnosis. The treatment segment is dominated North America Non-Alcoholic Steatohepatitis market in 2020. Based on sales channel the North America Non-Alcoholic Steatohepatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated North AmericaNon-Alcoholic Steatohepatitis market in 2020. Based on country, the North America Non-Alcoholic Steatohepatitis market is segmented into the US, Mexico, and Canada. The US dominated the North America non-alcoholic steatohepatitis market in 2020.

Cadila Pharmaceutical, Intercept Pharmaceutical, Novartis AG, Galmed Pharmaceutical, GENFIT, Prometheus Laboratories, Siemens Healthineers AG, and Laboratory Corporation of America are among the leading companies in North America non-alcoholic steatohepatitis market.

The List of Companies - North America Non-Alcoholic Steatohepatitis Market

● Cadila Pharmaceutical.

● Intercept Pharmaceutical.

● Novartis AG.

● Galmed Pharmaceutical.

● GENFIT.

● Prometheus Laboratories.

● Siemens Healthineers AG.

● Laboratory Corporation of America Holdings.

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 North America Non-Alcoholic Steatohepatitis Market – By Product

1.3.2 North America Non-Alcoholic Steatohepatitis Market – By Application

1.3.3 North America Non-Alcoholic Steatohepatitis Market – By Sales Channel

1.3.4 North America Non-Alcoholic Steatohepatitis Market – By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Non-Alcoholic Steatohepatitis Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.3 Experts Opinion

5. North America Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of NASH

5.1.2 Increasing Initiatives for the Awareness of NASH

5.2 Market Restraints

5.2.1 Lack of Established Guidelines in the Diagnosis and Management of NASH

5.2.2 Withdrawal of Drugs from Seeking Marketing Authorization for NASH

5.3 Market Opportunities

5.3.1 Growing Opportunities in Developing Nations

5.3.2 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity

5.4 Future Trends

5.4.1 Growing Clinical Trials Involving Combination Studies of Drugs

5.5 Impact Analysis

6. Non-alcoholic steatohepatitis (NASH) Market– North America Analysis

6.1 North America Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis

7. North America Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product

7.1 Overview

7.2 Product Market Revenue and Forecast Analysis (US$ Mn)

7.3 Vitamin E and Pioglitazone

7.3.1 Overview

7.3.2 Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

7.4 Ocaliva

7.4.1 Overview

7.4.2 Ocaliva Revenue and Forecast to 2028 (US$ Mn)

7.5 Elafibranor

7.5.1 Overview

7.5.2 Elafibranor Revenue and Forecast to 2028 (US$ Mn)

7.6 Selonsertib & Cenicriviroc

7.6.1 Overview

7.6.2 Selonsertib Revenue and Forecast to 2028 (US$ Mn)

7.7 Others

7.7.1 Overview

7.7.2 Others Revenue and Forecast to 2028 (US$ Mn)

8. North America Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application

8.1 Overview

8.2 Application Market Revenue and Forecast Analysis (US$ Mn)

8.3 Treatment

8.3.1 Overview

8.3.2 Treatment Market Revenue and Forecast to 2028 (US$ Mn)

8.4 Diagnosis

8.4.1 Overview

8.4.2 Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

9. North America Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel

9.1 Overview

9.2 Sales Channel Market Revenue and Forecast Analysis (US$ Mn)

9.3 Hospital Pharmacy

9.3.1 Overview

9.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.4 Retail Pharmacy

9.4.1 Overview

9.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.5 Online Provider

9.5.1 Overview

9.5.2 Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

10. North America Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Country Analysis

10.1 North America: Non-Alcoholic Steatohepatitis Market

10.1.1 Overview

10.1.3 North America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)

10.1.3.1 US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.1.1 US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.1.2 US: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)

10.1.3.1.3 US: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)

10.1.3.1.4 US: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)

10.1.3.2 Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.2.1 Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.2.2 Canada: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)

10.1.3.2.3 Canada: Non-Alcoholic Steatohepatitis Market, by Application , 2019–2028 (US$ Million)

10.1.3.2.4 Canada: Non-Alcoholic Steatohepatitis Market, by Sales Channel , 2019–2028 (US$ Million)

10.1.3.3 Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.3.1 Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.3.2 Mexico: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)

10.1.3.3.3 Mexico: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)

10.1.3.3.4 Mexico: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)

11. Industry Landscape

11.1 Overview

11.2 Organic Developments

11.2.1 Overview

11.3 Inorganic Developments

11.3.1 Overview

12. Company Profiles

12.1 Cadila Pharmaceuticals Ltd.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Intercept Pharmaceuticals, Inc

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Novartis AG

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Galmed Pharmaceuticals.

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 GENFIT.

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Prometheus Laboratories

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 Siemens Healthineers AG

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 Laboratory Corporation of America Holdings

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms

LIST OF TABLES.

Table 1. US Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 2. US Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 3. US Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 4. Canada: Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 5. Canada Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 6. Canada Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 7. Mexico: Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 8. Mexico Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 9. Mexico Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 10.   Organic Developments Done By Companies

Table 11.   Inorganic Developments Done By Companies

Table 12.   Glossary of Terms

The List of Companies - North America Non-Alcoholic Steatohepatitis Market

● Cadila Pharmaceutical.

● Intercept Pharmaceutical.

● Novartis AG.

● Galmed Pharmaceutical.

● GENFIT.

● Prometheus Laboratories.

● Siemens Healthineers AG.

● Laboratory Corporation of America Holdings.

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Non-Alcoholic Steatohepatitis market forecast.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in North America Non-Alcoholic Steatohepatitis market forecast, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the non-alcoholic steatohepatitis, as well as those hindering it.

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(North America Non-Alcoholic Steatohepatitis Market Forecast to 2028 )
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry